CGTLive®’s Weekly Rewind – January 23, 2026

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Ocugen Posts Positive Preliminary Phase 2 ArMaDa Trial Data of OCU410

Ocugen's OCU410 gene therapy shows promising results in reducing lesion growth for geographic atrophy, potentially transforming treatment for retinal health.

2. Jeffrey Goldberg, MD, PhD, on the Potential of Cell and Gene Therapy in Glaucoma

For Glaucoma Awareness Month, CGTLive interviewed the chair of ophthalmology at the Byers Eye Institute at Stanford University about the potential of cell and gene therapy for the condition.

3. Thoughts on Cilta-Cel's Boxed Warning

ImmunoLogic cohosts Janna Minehart, MD, and Joseph Fraietta, PhD, discussed the FDA’s 2025 decision to place a boxed warning on ciltacabtagene autoleucel (cilta-cel; Carvykti) for immune effector cell-associated enterocolitis (IEC-EC).

4. Brian Lin, PhD, on Using Genetics, Biomarkers, and Clinical Trial Readiness to Enhance ALS Care

The research portfolio director at the Muscular Dystrophy Association discussed how ongoing advances in ALS research may inform therapeutic development approaches.

5. The Key Role of Manufacturing in Cell Therapy Success

Minehart and Fraietta discussed lessons learned from 2025 and predictions for 2026 with regard to cell therapy manufacturing.